Psoriasis
Explore original articles, case reports, and podcasts that focus on psoriasis.
Resolving Hyperkeratotic Psoriasis: Mechanisms of Action and Additive Effects of Fixed-Combination Halobetasol Propionate and Tazarotene
August 2025 | Volume 24 | Issue 8 | Original Article | 795 | Copyright © August 2025
Background: Hyperkeratotic plaque psoriasis represents a distinct morphological variant that is difficult to treat with topical therapies because thick lesions may impede the pen...
Read MoreOpen-Label Study: Over-the-Counter Oat Flour/Oat Oil/ Oat Extract-containing Lotion With Avenanthramides for Sensitive Skin and Psoriasis
August 2025 | Volume 24 | Issue 8 | Original Article | 782 | Copyright © August 2025
Background: Psoriasis is a common skin condition that affects the physical and emotional well-being of patients. Moisturizers have been shown to significantly improve skin condit...
Read MoreStudy of Adjuvant Sensitive-Skin Cleansing and Moisturizing Regimen in Plaque Psoriasis
August 2025 | Volume 24 | Issue 8 | Original Article | 739 | Copyright © August 2025
Background: Epidermal barrier dysfunction is a key feature of plaque psoriasis. Skincare improves epidermal barrier function and is an increasingly recommended part of psoriasis ...
Read MoreHalobetasol Propionate/Tazarotene Lotion for Scalp Psoriasis: Efficacy in Itch Reduction, Disease Clearance, and Hair Appearance
August 2025 | Volume 24 | Issue 8 | Original Article | 752 | Copyright © August 2025
Scalp involvement in plaque psoriasis is accompanied by itching and scaling that reduce quality of life and exacerbate psoriatic-associated hair loss. Challenges for the topical treatment of scal...
Read MoreComparative Efficacy of Deucravacitinib and Adalimumab for Scalp Psoriasis: An Indirect Treatment Comparison
August 2025 | Volume 24 | Issue 8 | Original Article | 788 | Copyright © August 2025
Background: Plaque psoriasis of the scalp, a common psoriasis location, remains difficult to manage. The comparative efficacy of newer oral agents, such as deucravacitinib, versus ...
Read MoreChatGPT Improves Readability of Patient Education Materials for Hidradenitis Suppurativa and Psoriasis
August 2025 | Volume 24 | Issue 8 | Features | 828 | Copyright © August 2025
Deucravacitinib With Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis
August 2025 | Volume 24 | Issue 8 | Original Article | 744 | Copyright © August 2025
Background: To assess the effectiveness, safety, and quality of life in patients who received topical calcipotriene/betamethasone dipropionate (C/BD) foam added to oral deucravacitini...
Read MoreTwo-Year Treatment Persistence of Guselkumab vs Other Biologics in Plaque Psoriasis Patients
August 2025 | Volume 24 | Issue 8 | Original Article | 762 | Copyright © August 2025
Objective: The study objective was to compare long-term treatment persistence between patients initiating guselkumab vs 3 commonly prescribed biologics in the United States.Read MoreClinical Profile of Halobetasol Propionate 0.01%/ Tazarotene 0.045% Lotion in Patients With Hyperkeratotic Plaque Psoriasis
June 2025 | Volume 24 | Issue 6 | Original Article | 590 | Copyright © June 2025
Background: Hyperkeratotic psoriatic plaques, characterized by considerable elevation and scaling, present treatment challenges with topical therapy. This post hoc analysis of tw...
Read MorePDE4 Inhibitors: Bridging Molecular Insights With Clinical Impact
June 2025 | Volume 24 | Issue 6 | Original Article | 631 | Copyright © June 2025
Read MoreSpesolimab for the Treatment of Generalized Pustular Psoriasis Flares
March 2025 | Volume 24 | Issue 3 | Original Article | 242 | Copyright © March 2025
Background: Generalized pustular psoriasis (GPP) is a rare, life-threatening neutrophilic skin condition characterized by widespread sterile eruptions. Treatment approaches vary ...
Read MoreGuselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc Analyses
February 2025 | Volume 24 | Issue 2 | Original Article | 196 | Copyright © February 2025
Background: The pivotal Phase 3 VOYAGE 1 and VOYAGE 2 studies established the robust efficacy and safety of guselkumab for up to 5 years in patients with moderate-to-severe psori...
Read MoreAn Unusual Case of Psoriasiform Dermatitis Treated With Dual Biologic Therapy and Literature Review
February 2025 | Volume 24 | Issue 2 | Case Reports | 207 | Copyright © February 2025
Previously believed to be of distinct immunopathogenesis, atopic dermatitis (AD) and psoriasis (PsO) spectrum may permit immunologic shifts to favor the opposing inflammatory states following bio...
Read MoreStructural Insights: What Makes Some IL-23 Biologics More Effective in Psoriasis
October 2024 | Volume 23 | Issue 10 | Features | 903 | Copyright © October 2024
Read MoreSelective Tyrosine Kinase 2 (TYK2) Inhibition in Plaque Psoriasis
August 2024 | Volume 23 | Issue 8 | Original Article | 645 | Copyright © August 2024
Members of the Janus kinase (JAK) superfamily, comprising tyrosine kinase 2 (TYK2) and JAK1, JAK2, and JAK3, mediate signaling by cytokines (eg, interleukin [IL]-23) involved in psoriasis pathoge...
Read MoreTildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis
August 2024 | Volume 23 | Issue 8 | Original Article | 612 | Copyright © August 2024
Background: Tildrakizumab is a humanized anti-interleukin-23 p19 monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis. This report describes real-world effectiveness a...
Read MoreSafety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel
August 2024 | Volume 23 | Issue 8 | Original Article | 592 | Copyright © August 2024
Background: Plaque psoriasis is a chronic, relapsing systemic illness that has a significant effect on quality of life. Bimekizumab is the first monoclonal antibody to target bot...
Read MoreBenefits Over Five Years of Ixekizumab Treatment in Patients With Psoriasis Involving Challenging Body Areas
August 2024 | Volume 23 | Issue 8 | Original Article | 619 | Copyright © August 2024
Background: Psoriasis involving challenging body areas, such as the scalp, face, palmoplantar surfaces, or nails, can be challenging to treat and negatively affects patient outco...
Read MoreEfficacy and Safety of Secukinumab in the Treatment of Psoriasis in Patients with Skin Phototypes IV to VI
August 2024 | Volume 23 | Issue 8 | Original Article | 600 | Copyright © August 2024
Background: There is a paucity of data on the treatment of psoriasis in patients with skin of color – a diverse population among whom variations in clinical features and hi...
Read MoreThe Impact of At-Home Narrow-Band UVB Phototherapy for Mild-to-Severe Psoriasis: A Retrospective, Multicenter, Observational Study
August 2024 | Volume 23 | Issue 8 | Editorials | e169 | Copyright © August 2024
© 2025 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
